Amira Pharmaceuticals

amirapharm.com

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

NEUROBO PHARMACEUTICALS, INC. AND DONG-A ST CO. LTD. ANNOUNCE STRATEGIC COLLABORATION

NeuroBo Pharmaceuticals, Inc. | September 16, 2022

news image

NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co., Ltd. announced that they have entered into a conditional exclusive license agreement for NeuroBo to develop and commercialize DA-1241 and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis obesity and type 2 diabetes. DA-1241 is a novel G-Protein-Coupled Receptor 119 agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucos...

Read More

BUSINESS INSIGHTS

KEMPHARM ANNOUNCES STRATEGIC ACQUISITION OF ARIMOCLOMOL FROM ORPHAZYME, EXPANDING ITS RARE CNS DISEASES PIPELINE

KemPharm | May 16, 2022

news image

Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with the U.S. Food and Drug Administration as early as the First Quarter of 2023 CELEBRATION, Fla., May 15, 2022 KemPharm, Inc. a specialty pharmaceutical company focused on the discovery and developmen...

Read More

CANNABIS INDUSTRY GIANT WAYOFLEAF.COM EXPANDS HEALTH-SPECIFIC CONTENT, INTRODUCES MEDICAL REVIEW TEAM

Prnewswire | September 30, 2020

news image

In a bid to improve the quality and availability of information on health-specific cannabis use, industry giant WayofLeaf.com has introduced a team of doctors and health experts to review thousands of topics relating to the use of medical cannabis and CBD for specific health conditions. The website, which for years has provided a reliable informational resource for medical cannabis patients, believes it is time for cannabis users of all types to have access to trustworthy, research-backed conten...

Read More

RESEARCH

IDBS LAUNCHES POLAR™ IN A NEW PRODUCT CATEGORY THAT AIMS TO STREAMLINE AND SPEED UP BIOPHARMACEUTICAL DEVELOPMENT

IDBS | December 07, 2020

news image

IDBS, a product informatics arrangement supplier for biotech and pharma, today reported the dispatch of Polar™, building up another item classification, BioPharma Lifecycle Management (BPLM), pointed toward smoothing out medication advancement and assembling in biopharma research. The advancement of biologics is a unique cycle and the individuals who are best should have the option to adjust to changes in cycle or innovation quickly. IDBS information has discovered that with...

Read More
news image

BUSINESS INSIGHTS

NEUROBO PHARMACEUTICALS, INC. AND DONG-A ST CO. LTD. ANNOUNCE STRATEGIC COLLABORATION

NeuroBo Pharmaceuticals, Inc. | September 16, 2022

NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co., Ltd. announced that they have entered into a conditional exclusive license agreement for NeuroBo to develop and commercialize DA-1241 and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis obesity and type 2 diabetes. DA-1241 is a novel G-Protein-Coupled Receptor 119 agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucos...

Read More
news image

BUSINESS INSIGHTS

KEMPHARM ANNOUNCES STRATEGIC ACQUISITION OF ARIMOCLOMOL FROM ORPHAZYME, EXPANDING ITS RARE CNS DISEASES PIPELINE

KemPharm | May 16, 2022

Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with the U.S. Food and Drug Administration as early as the First Quarter of 2023 CELEBRATION, Fla., May 15, 2022 KemPharm, Inc. a specialty pharmaceutical company focused on the discovery and developmen...

Read More
news image

CANNABIS INDUSTRY GIANT WAYOFLEAF.COM EXPANDS HEALTH-SPECIFIC CONTENT, INTRODUCES MEDICAL REVIEW TEAM

Prnewswire | September 30, 2020

In a bid to improve the quality and availability of information on health-specific cannabis use, industry giant WayofLeaf.com has introduced a team of doctors and health experts to review thousands of topics relating to the use of medical cannabis and CBD for specific health conditions. The website, which for years has provided a reliable informational resource for medical cannabis patients, believes it is time for cannabis users of all types to have access to trustworthy, research-backed conten...

Read More
news image

RESEARCH

IDBS LAUNCHES POLAR™ IN A NEW PRODUCT CATEGORY THAT AIMS TO STREAMLINE AND SPEED UP BIOPHARMACEUTICAL DEVELOPMENT

IDBS | December 07, 2020

IDBS, a product informatics arrangement supplier for biotech and pharma, today reported the dispatch of Polar™, building up another item classification, BioPharma Lifecycle Management (BPLM), pointed toward smoothing out medication advancement and assembling in biopharma research. The advancement of biologics is a unique cycle and the individuals who are best should have the option to adjust to changes in cycle or innovation quickly. IDBS information has discovered that with...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us